Several groundbreaking medications are reshaping glucose management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as promising choices. Retatrutide, a double GIP and GLP-1 site stimulant, exhibits significant body mass decrease along with better blood sugar levels. Cagrillintide, another GLP-1 agonist, is currently in clin